UNSPSC 51434703: Temocapril hydrochloride

This classification denotes an ace inhibitor with the molecular formula C23H28N2O5S2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8G820I95VP, chemically known as 1,4-thiazepine-4-(5h)-acetic acid, 6-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-, monohydrochloride, (2s-(2alpha,6beta(r*)))- but more generally known as temocapril hydrochloride, which bears US NIH Compound Identifier 71322.

UNSPSC 51434703 Temocapril hydrochloride is a Commodity code that captures prescription pharmaceuticals and advanced life support medications procured by state and local public health agencies, fire departments, and health authorities for emergency medical services and pharmacy benefit programs. State and local governments buy specific drug products under this code—individual medications identified by National Drug Code (NDC), dosage, strength, and unit quantity—either as standalone line items within larger medication procurement contracts or as part of broader generic pharmaceutical cooperative purchasing agreements. Issuing bodies include city purchasing departments acting on behalf of fire rescue services, state health and human services commissions managing pharmacy benefits for state employees and beneficiaries, and cooperative purchasing alliances that aggregate demand across multiple state and local jurisdictions. The work involves supplying finished pharmaceutical products meeting FDA, cGMP, and DSCSA compliance; maintaining strict expiration-date and shelf-life requirements; and arranging logistics including freight, delivery windows, and replacement of expired inventory before contracted expiration dates.

Recent activity spans Florida, Texas, and Minnesota-based cooperative purchasing. The City of Tampa's Purchasing Department issued IFB 26-P-00188 in April 2026, soliciting advanced life support medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) for Tampa Fire Rescue with an estimated contract value of $40,000 and a one-year term with renewal options; bids were due April 8, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program, signaling early-stage procurement planning for direct pharmacy contracting outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 deadline; the contract term runs two years from July 1, 2026, with distribution through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and pricing evaluated at 75 percent weight. MMCAP's participation includes Oregon, broadening the geographic reach of the cooperative vehicle.